All articles by GlobalData Healthcare

Improving early detection and treatment of liver cancer

Outcomes for liver cancer patients are highly stage dependent. Interventions designed to be curative, such as minimally invasive ablation, tumour…
Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisition

On 23 February, Gilead Sciences announced its $7.8bn acquisition of Arcellx, primarily to secure rights to anitocabtagene autoleucel (anito-cel), an…
Transient but transformative: Sanofi’s mRNA CAR-T enters in vivo race

In a recent article in Molecular Therapy, Sanofi presented preclinical data for an in vivo CAR-T platform that reengineers T…
Autologous versus allogeneic: how cell therapy development is changing in oncology

Cell therapies have gained steam in oncology since Novartis’s Kymriah (tisagenlecleucel) became the first chimeric antigen receptor (CAR)-T cell therapy…
Wegovy portfolio growth shifts to the pill as injectable sales forecast to plateau

In December 2025, the FDA approved the first-ever GLP-1 pill for chronic weight management - Novo Nordisk’s oral formulation of…

US vaccine manufacturers set to lose as RFK pushes for weaker vaccine mandates

Earlier this year, the Trump Administration, backed by US Health and Human Services Secretary Robert F Kennedy (RFK) Jr, a…
Multiple Myeloma Awareness Month: the current and future landscape

March is Multiple Myeloma (MM) Awareness Month, which raises awareness, action, and amplifies the voices of individuals impacted by MM,…
SLE and LN market expected to reach $5.9bn across 7MM by 2034

A notable growth in the systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major markets (7MM;…
Significant opportunities exist in the global pain market for novel mechanisms and modalities

Pain is a multifaceted, highly heterogeneous disorder that is treated using analgesics. There is a lack of diversity within the…
AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals

Under the three-year deal, AbbVie agreed to lower prices on certain Medicaid drugs and expand distribution through the TrumpRx direct-to-patient…